These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 27423779)

  • 1. Lanreotide Autogel in the Treatment of Idiopathic Refractory Diarrhea: Results of an Exploratory, Controlled, Before and After, Open-label, Multicenter, Prospective Clinical Trial.
    Bisschops R; De Ruyter V; Demolin G; Baert D; Moreels T; Pattyn P; Verhelst H; Lepoutre L; Arts J; Caenepeel P; Ooghe P; Codden T; Maisonobe P; Petrens E; Tack J
    Clin Ther; 2016 Aug; 38(8):1902-1911.e2. PubMed ID: 27423779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
    Vinik AI; Wolin EM; Liyanage N; Gomez-Panzani E; Fisher GA;
    Endocr Pract; 2016 Sep; 22(9):1068-80. PubMed ID: 27214300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.
    Fisher GA; Wolin EM; Liyanage N; Pitman Lowenthal S; Mirakhur B; Pommier RF; Shaheen M; Vinik A;
    Oncologist; 2018 Jan; 23(1):16-24. PubMed ID: 29038234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study.
    Caron PJ; Bevan JS; Petersenn S; Houchard A; Sert C; Webb SM;
    Pituitary; 2016 Apr; 19(2):149-57. PubMed ID: 26603536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.
    Caron PJ; Bevan JS; Petersenn S; Flanagan D; Tabarin A; Prévost G; Maisonobe P; Clermont A;
    J Clin Endocrinol Metab; 2014 Apr; 99(4):1282-90. PubMed ID: 24423301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.
    Lucas T; Astorga R;
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):320-6. PubMed ID: 16918950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria.
    Rinke A; Maintz C; Müller L; Weber MM; Lahner H; Pavel M; Saeger W; Houchard A; Ungewiss H; Petersenn S
    Exp Clin Endocrinol Diabetes; 2021 Jul; 129(7):500-509. PubMed ID: 34293802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly.
    Caron P; Cogne M; Raingeard I; Bex-Bachellerie V; Kuhn JM
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):209-14. PubMed ID: 16430722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.
    Caron P; Beckers A; Cullen DR; Goth MI; Gutt B; Laurberg P; Pico AM; Valimaki M; Zgliczynski W
    J Clin Endocrinol Metab; 2002 Jan; 87(1):99-104. PubMed ID: 11788630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
    Caron P; Bex M; Cullen DR; Feldt-Rasmussen U; Pico Alfonso AM; Pynka S; Racz K; Schopohl J; Tabarin A; Valimaki MJ;
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):734-40. PubMed ID: 15163338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
    Fisher GA; Wolin EM; Liyanage N; Lowenthal SP; Mirakhur B; Pommier RF; Shaheen M; Vinik AI;
    Endocr Pract; 2018 Mar; 24(3):243-255. PubMed ID: 29547049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective.
    Bevan JS; Newell-Price J; Wass JA; Atkin SL; Bouloux PM; Chapman J; Davis JR; Howlett TA; Randeva HS; Stewart PM; Viswanath A
    Clin Endocrinol (Oxf); 2008 Mar; 68(3):343-9. PubMed ID: 17892497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Acromegaly in Routine Clinical Practice in Germany, Austria and Switzerland.
    Störmann S; Schopohl J; Bullmann C; Terkamp C; Christ-Crain M; Finke R; Flitsch J; Kreitschmann-Andermahr I; Luger A; Stalla G; Houchard A; Helbig D; Petersenn S
    Exp Clin Endocrinol Diabetes; 2021 Mar; 129(3):224-233. PubMed ID: 33285601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient satisfaction and preferences of lanreotide Autogel treatment in acromegaly.
    Witek P; Mucha S; Ruchała M
    Endokrynol Pol; 2016; 67(6):572-579. PubMed ID: 28042650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.
    Ruszniewski P; Valle JW; Lombard-Bohas C; Cuthbertson DJ; Perros P; Holubec L; Delle Fave G; Smith D; Niccoli P; Maisonobe P; Atlan P; Caplin ME;
    Dig Liver Dis; 2016 May; 48(5):552-558. PubMed ID: 26917486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers.
    Antonijoan RM; Barbanoj MJ; Cordero JA; Peraire C; Obach R; Vallès J; Chérif-Cheikh R; Torres ML; Bismuth F; Montes M
    J Pharm Pharmacol; 2004 Apr; 56(4):471-6. PubMed ID: 15099442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study.
    Martín-Richard M; Massutí B; Pineda E; Alonso V; Marmol M; Castellano D; Fonseca E; Galán A; Llanos M; Sala MA; Pericay C; Rivera F; Sastre J; Segura A; Quindós M; Maisonobe P;
    BMC Cancer; 2013 Sep; 13():427. PubMed ID: 24053191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects : evidence for injection interval of up to 2 months.
    Trocóniz IF; Cendrós JM; Peraire C; Ramis J; Garrido MJ; Boscani PF; Obach R
    Clin Pharmacokinet; 2009; 48(1):51-62. PubMed ID: 19071884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.
    Meijer E; Visser FW; van Aerts RMM; Blijdorp CJ; Casteleijn NF; D'Agnolo HMA; Dekker SEI; Drenth JPH; de Fijter JW; van Gastel MDA; Gevers TJ; Lantinga MA; Losekoot M; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Wetzels JF; Zietse R; Gansevoort RT;
    JAMA; 2018 Nov; 320(19):2010-2019. PubMed ID: 30422235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life in patients with acromegaly receiving lanreotide autogel: a real-world observational study.
    Bolanowski M; Hubalewska-Dydejczyk A; Kos-Kudła B; Ruchała M; Witek P; Zgliczyński W; Houchard A; Bartmańska M
    Endokrynol Pol; 2021; 72(5):512-519. PubMed ID: 34647602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.